Subscribe to our newsletter
Menu
World-renowned perinatal epidemiologists support the design and data analysis of every study, ensuring rigor and success.
Real-time reports available at individual and aggregate levels and across interim intervals.
Expertly-designed end to end security protocols protect against advanced threats across the web.
Complex interlinked algorithms result in a personalized experience, ensuring data hygiene.
Proprietary engagement system ensures participant engagement throughout the course of study.
Our highly experienced team includes expert physicians and scientists ready to help solve your most complex challenges.
Our experienced maternal health physicians, epidemiologists, and medical writers use internal and external resources to provide you with up-to-date, comprehensive reports on medication and vaccine safety during pregnancy.
Whether your product is designed for use by a small or large number of pregnant people, we have an economical solution tailored to your needs.
Our team of distinguished perinatal pharmacoepidemiologists, biostatisticians, medical writers, and regulatory experts support your organization to ensure your needs are fully satisfied.
Capable of rapid study deployment in any part of the world, our global teams quickly assemble technical infrastructure and use native technical tools to access data rapidly and safely.
Observational, prospective, cohort studies. All study documents, including study protocol, informed consent form, questionnaire modules, and statistical analysis plans, are reviewed and approved by a world-class external scientific advisory committee.
Information is collected in compliance with security requirements. Secure intranet communication, customizable participant modules, and active management of safety signals is in accordance with GVP Module IX.
Our highly skilled team provides real-time communication with study participants. Study awareness campaigns are deployed and we produce personalized communications and solicit feedback.
RSV-PR is an observational research study designed to learn more about the ongoing health of pregnant individuals who received the RSV vaccine during the third trimester of pregnancy, as well as their infant after they’re born, compared to those who choose to not receive the vaccine.
The study team is looking for providers with patients aged 18 to 50 who are pregnant and either plan to receive the recommended vaccine in the third trimester, recently received the recommended Respiratory Syncytial Virus (RSV) vaccine at or after week 32 of pregnancy or have chosen to not receive the RSV vaccine. Providers may contact the registry at:
The Pregistry International Pregnancy Exposure Registry (PIPER) is a study designed to develop an understanding of the safety profile of medications and vaccines when used during pregnancy. Online surveys are used to collect information about the pregnancy and the baby up to 12 months after birth. Participants enroll during pregnancy and must be 18 years or older.
The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is a research study that focuses on learning about COVID-19 vaccines during pregnancy. Participants are 18 years of age or older, pregnant at the time of enrollment, and have had a COVID-19 vaccine during this pregnancy or just before it.
With more than 360 participants and counting, the COVID-19 International Drug Pregnancy Registry (COVID-PR) focuses on monoclonal antibodies and antivirals used to treat COVID-19 during pregnancy. Participants are age 18 or over, currently pregnant or gave birth just before enrolling, and were treated for COVID-19 during pregnancy.
The IRCEP studied pregnant and recently pregnant people who were or may have been infected with SARS-CoV-2, the virus that causes COVID-19.
Pharmaceutical partners: Johnson & Johnson and Regeneron.
Academic partner: Department of Epidemiology, Harvard TH Chan School of Public Health.
We studied an international sample of 6,894 pregnant people from 64 countries to learn about how the COVID-19 pandemic impacted their mental health and wellbeing.
Academic partner: Department of Psychiatry, Massachusetts General Hospital
We asked 17,871 study participants from 16 countries if they would get a COVID-19 vaccine for themselves while pregnant, or whether they would get vaccinated for their children.
Academic partner: Department of Global Health and Population, Harvard TH Chan School of Public Health
